Q1 EPS Estimates for Gossamer Bio Reduced by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright reduced their Q1 2025 EPS estimates for Gossamer Bio in a research note issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to analysts’ expectations of $7.02 million.

Separately, Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio currently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $1.35 on Thursday. The company has a market cap of $306.75 million, a price-to-earnings ratio of -4.22 and a beta of 1.86. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55. The company has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $0.98.

Institutional Investors Weigh In On Gossamer Bio

A number of large investors have recently modified their holdings of the company. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio during the third quarter worth $67,000. The Manufacturers Life Insurance Company lifted its holdings in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after buying an additional 74,920 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after buying an additional 1,520,721 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after acquiring an additional 442,895 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its holdings in shares of Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after acquiring an additional 9,162,117 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.